Skip to Main Content

Latest News

Sanacora, Wilkinson Receive $12.6M in Funding for Ketamine Study

Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry, and Samuel Wilkinson, MD, associate professor of psychiatry, have received $12.6 million in funding from the Patient-Centered Outcomes Research Institute (PCORI) for the study, “Comparative Effectiveness of Racemic Ketamine versus S-Ketamine (Spravato) for Depression.”

Read more
  • Ketamine and the Neurobiology of Depression: Toward Next-generation Rapid-acting Antidepressant Treatments

    John Krystal, MD, Robert L. McNeil, Jr. Professor of Translational Research and Professor of Psychiatry, of Neuroscience, and of Psychology; and Irina Esterlis, PhD, associate professor of psychiatry, are first and senior authors, respectively, of a review published in Proceedings of the National Academy of Sciences Perspective that considers what scientists have learned from studies of ketamine and to suggest future directions for the optimization of rapid-acting antidepressant treatment.

    Source: Proceedings of the National Academy of Sciences Perspective
    Read more
  • Wilkinson, Rhee Awarded NIH Research Project Grants

    Samuel Wilkinson, MD, associate professor of psychiatry, and Greg Rhee, PhD, assistant professor adjunct of psychiatry, have been awarded two grants through the National Institutes of Health Research Project Grants Program.

    Read more
  • Long term Structural and Functional Neural Changes Following a Single Infusion of Ketamine in PTSD

    Or Duek, PhD, assistant professor adjunct of psychiatry, and Ilan Harpaz-Rotem, PhD, professor of psychiatry and of psychology, are first and senior authors, respectively of a study published in Neuropsychopharmacology that tests the potential of a single infusion of ketamine, followed by brief exposure therapy, to enhance post-retrieval extinction of post-traumatic stress disorder trauma memories.

    Source: Neuropsychopharmacology
    Read more
  • Ketamine: Handle With Care

    Off-label, unsupervised use of ketamine has skyrocketed since regulatory changes were put in place at the height of the COVID pandemic. Yale psychiatrist Gerard Sanacora, a worldleader in ketamine research and clinical use, discusses some of the risks patients may be taking.

    Read more
  • Sanacora, Holmes Discuss Ketamine's Impact on Depression on Podcast

    Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry, and Sophie Holmes, PhD, assistant professor of psychiatry, Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry, and Sophie Holmes, PhD, assistant professor of psychiatry, spoke about depression and mental health in Parkinson’s disease, as well as how ketamine can treat depression, on the Trembling EMT Podcast.

    Source: Trembling EMT Podcast
    Read more
  • Time for a National Ketamine Registry, Experts Say

    Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry, spoke to Medscape about the effort to create a ketamine registry to collect data on dosage, treatment frequency, adverse events, and long-term outcomes in patients receiving the therapy for depression and other mental health conditions.

    Source: Medscape
    Read more